Brokerages Set Solventum Co. (NYSE:SOLV) PT at $79.86

Shares of Solventum Co. (NYSE:SOLV) have earned a consensus recommendation of “Hold” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $79.86.

A number of equities analysts recently commented on SOLV shares. Mizuho boosted their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Bank of America boosted their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler boosted their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Finally, The Goldman Sachs Group raised their price target on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd.

Solventum Trading Down 1.0 %

NYSE SOLV opened at $74.78 on Wednesday. Solventum has a one year low of $47.16 and a one year high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market capitalization of $12.94 billion and a price-to-earnings ratio of 27.19. The company’s 50-day simple moving average is $75.51 and its two-hundred day simple moving average is $71.87.

Institutional Investors Weigh In On Solventum

A number of large investors have recently modified their holdings of the business. Norges Bank acquired a new stake in Solventum in the 4th quarter worth approximately $203,740,000. Hotchkis & Wiley Capital Management LLC purchased a new position in shares of Solventum in the third quarter worth $125,488,000. Trian Fund Management L.P. lifted its stake in shares of Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after buying an additional 1,765,676 shares during the period. Boston Partners purchased a new stake in shares of Solventum during the fourth quarter valued at $110,378,000. Finally, Independent Franchise Partners LLP increased its position in shares of Solventum by 105.0% in the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company’s stock valued at $105,904,000 after acquiring an additional 821,272 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.